Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ACACB | O00763 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9170209 | 0.85 | EPHX2 (0.50) | TP53TSHRACACBMEN1KMT2A | |
| SCHEMBL16578246 | 0.85 | NOS3 (0.51) | ALDH1A1EPHX2 | |
| SCHEMBL9163486 | 0.85 | EPHX2 (0.50) | TP53TSHRACACBMEN1KMT2A | |
| SCHEMBL18328239 | 0.85 | PTPRB (0.55) | TP53TSHRACACBMEN1KMT2A | |
| SCHEMBL10604896 | 0.83 | TP53 (0.55) | TP53TSHRACACBMEN1KMT2A | |
| SCHEMBL5691937 | 0.82 | ACACB (0.49) | TP53TSHRACACBMEN1KMT2A | |
| SCHEMBL6957067 | 0.82 | ACACB (0.49) | TP53TSHRACACBMEN1KMT2A | |
| SCHEMBL13534766 | 0.81 | ESR1 (0.47) | ACACBLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL14590363 | 0.81 | ATM (0.50) | ACACBALDH1A1NPC1RAB9AL3MBTL1 | |
| SCHEMBL5546946 | 0.81 | ESR1 (0.65) | TSHRKMT2ACA1CA2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428076-B2 | Soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10030027-B2 | Soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030027-B2 | Soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME LLC | 2017-06-22 | — | — | US | disclosed |
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME LLC | 2017-06-22 | — | — | US | disclosed |
| US-6075120-A | A HETERODIMERIC PEPTIDE MODULATOR; FOR THE TREATMENT OF ASTHMA; FOR THE TREATMENT OF PAIN; ANTIINFLAMMATORY AGENTS | CORTECH, INC. (US) | 2000-06-13 | — | — | US | disclosed |
| US-5863899-A | ANALGESICS AND ANTIINFLAMMATORY AGENT; A MORPHINE OR DERIVATIVE IS ATTACHED TO BRANDYKININ ANTAGONIST PEPTIDE BY MALEIMIDO OR AMINO ACID ANALOG LINKER | CORTECH, INC. (US) | 1999-01-26 | — | — | US | disclosed |
| EP-0671941-A4 | BRADYKININ ANTAGONISTS. | CORTECH INC (US) | 1996-05-29 | — | — | EP | disclosed |
| EP-0671941-A1 | BRADYKININ ANTAGONISTS | CORTECH, INC. (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994011021-A1 | BRADYKININ ANTAGONISTS | CORTECH, INC. (US) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A1, GUCY1A2, PDE2A | TP53 2280/4885TSHR 379/4885ACACB 4312/4885 |
| US-10030027-B2 | Soluble guanylate cyclase stimulators | GUCY1A1, GUCY1A2, PDE2A | TP53 2280/4885TSHR 379/4885ACACB 4312/4885 |
| US-10428076-B2 | Soluble guanylate cyclase stimulators | GUCY1A1, GUCY1A2, PDE2A | TP53 2280/4885TSHR 379/4885ACACB 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.